RSS

HIV-1

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported the positive topline results from the ATLAS Phase III study investigating a novel, long acting injectable two-drug regimen for the treatment of HIV-1. more

News

A new prophylactic vaccine aimed at providing immunity against several types of HIV-1 infection has provided promising results in a Phase I/IIa clinical trial, recently published in The Lancet, of just under 400 patients. more

News

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir/rilpivirine) — a two-drug regimen, once-daily, single pill for the treatment of HIV-1. more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Juluca treatment for HIV-1. more

News

The US Food and Drug Administration (FDA) has approved the first two-drug regimen for certain patients with human immunodeficiency virus type 1 (HIV-1). more

News

Janssen has announced that the European Commission (EC) has approved its darunavir-based single-tablet regimen (STR), Symtuza▼, for the treatment of HIV-1 in adults and adolescents in Europe. more

News

Aptalis Pharmaceutical Technologies has announced that the European Commission granted marketing authorisation for a new paediatric indication of a new oral granule formulation of Gilead Sciences, Inc.’s Viread for HIV infected children... more

Technology